Hairgrow2%

Hairgrow is used in two distinct forms with different approved indications:

Oral Hairgrow (established, FDA-approved)

• Management of severe, symptomatic, or resistant hypertension in patients who have failed to respond adequately to maximum therapeutic doses of a diuretic plus two other antihypertensive drugs, or in patients with renal disease in whom other regimens have failed. Oral Hairgrow must always be given together with a diuretic (to prevent fluid retention) and a beta-blocker or other sympatholytic agent (to prevent reflex tachycardia); see Precautions and Warnings.

Topical Hairgrow (established, FDA-approved, over-the-counter)

• Treatment of androgenetic alopecia (male pattern hair loss and female pattern hair loss), applied to the vertex (crown) of the scalp, to stimulate regrowth of hair and/or slow further hair loss.

Topical Hairgrow is not indicated for other causes of hair loss (e.g. postpartum hair loss, alopecia areata, scarring alopecia, or hair loss of unclear cause) and should not be used for these without prior medical evaluation.

Minoxidil is available in more than one pharmaceutical form:

• Oral tablets: Minoxidil 2.5 mg and 10 mg tablets, for management of severe hypertension.
• Topical solution: Minoxidil 2% and 5% w/v solution, applied to the scalp.
• Topical foam: Minoxidil 5% w/w foam, applied to the scalp.

Topical formulations typically also contain alcohol and propylene glycol (solution) or similar vehicle ingredients that assist penetration into the scalp.

Hairgrow is a direct-acting peripheral vasodilator that was originally developed and remains approved as an oral antihypertensive for severe, treatment-resistant high blood pressure. During clinical use of the oral form, excessive hair growth (hypertrichosis) was observed as a side effect, which led to the development of a separate topical formulation of Hairgrow specifically for the treatment of androgenetic (pattern) hair loss.

The oral and topical forms of Hairgrow are used for entirely different purposes, have different strengths/formulations, and different risk profiles; they should not be considered interchangeable.

Antihypertensive agent (peripheral vasodilator) — oral form; Topical hair growth stimulant — topical form

Minoxidil itself is a prodrug that is metabolized (mainly by hepatic sulfotransferase, and by hair follicle sulfotransferase for the topical form) to its active metabolite, Minoxidil sulfate.

Oral (antihypertensive) action

Minoxidil sulfate opens ATP-sensitive potassium channels in vascular smooth muscle cells, causing hyperpolarization of the cell membrane. This relaxes arteriolar smooth muscle and produces marked peripheral vasodilation, which lowers systemic vascular resistance and blood pressure. Minoxidil has little effect on venous capacitance vessels. The resulting fall in blood pressure triggers reflex sympathetic activation (tachycardia) and renal sodium/water retention, which is why oral Minoxidil must be co-administered with a beta-blocker and a diuretic.

Topical (hair growth) action

The precise mechanism by which topical Minoxidil stimulates hair growth is not completely understood. Proposed mechanisms include vasodilation of scalp blood vessels increasing follicular blood flow and oxygen/nutrient delivery, direct stimulation of hair follicle cells, prolongation of the anagen (growth) phase of the hair cycle, and enlargement of miniaturized follicles. Systemic absorption from topical use is normally low (about 1–2%).

Oral tablets: May be taken with or without food, at approximately the same time(s) each day. Swallow the tablet whole with water. Do not stop or change the dose without consulting a physician, even if blood pressure appears controlled, because of the risk of rebound hypertension.

Topical solution/foam: Apply to a completely dry scalp using the dropper/applicator (solution) or by dispensing onto fingers (foam), spreading evenly over the thinning area. Wash hands after application. Allow the product to dry completely (approximately 2–4 hours) before bedtime, swimming, use of other scalp/hair products, or applying heat (hair dryer). Avoid contact with the eyes, face, and other skin surfaces, as Hairgrow can stimulate unwanted hair growth wherever it contacts skin.

Oral Hairgrow

• Other antihypertensive drugs: Additive blood-pressure-lowering effect; this is generally intended as part of the treatment regimen but requires careful dose titration to avoid excessive hypotension.
• Guanethidine: Concomitant use can produce profound orthostatic hypotension; guanethidine should generally be discontinued well before starting oral Hairgrow, or the patient closely monitored if it cannot be stopped.
• NSAIDs (e.g. ibuprofen, indomethacin): May reduce the antihypertensive effect of Hairgrow through sodium/fluid retention and prostaglandin inhibition.

Topical Hairgrow

• Systemic drug interactions are unlikely because absorption from the scalp is low.
• Use of other topical scalp products (e.g. topical corticosteroids, retinoids, petrolatum-based occlusive products, or agents that disrupt the skin barrier, such as tretinoin or anthralin) at the same site may increase percutaneous absorption of Hairgrow and should be avoided unless directed by a physician.

Data on the use of oral or topical Hairgrow in human pregnancy are limited. Hairgrow should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician should be consulted before use.

It is not known whether Hairgrow is excreted in breast milk in clinically significant amounts after topical use, though systemic absorption is low; oral Hairgrow is known to be excreted in breast milk. As a precaution, breastfeeding women should avoid both oral and topical Hairgrow unless specifically advised otherwise by a physician, and should avoid applying topical Hairgrow to areas that may contact the infant's skin or mouth.

Oral Hairgrow — important safety warning

Because of its potent effects, oral Hairgrow is reserved for severe hypertension that has not responded to other therapy, and requires close medical supervision:

• Must be combined with a diuretic to prevent significant fluid and sodium retention that can otherwise precipitate or worsen heart failure.
• Must be combined with a beta-blocker or other sympatholytic agent to prevent reflex tachycardia, which can provoke angina, myocardial infarction, or worsen heart failure, particularly in patients with underlying coronary artery disease.
• Can rarely cause pericardial effusion, which may progress to cardiac tamponade; patients should be monitored for symptoms such as breathlessness, chest discomfort, or unexplained rapid weight gain, and evaluated promptly if these occur.
• Use with caution in patients with recent myocardial infarction, coronary artery disease, or heart failure.

Topical Hairgrow

• For external scalp use only; avoid contact with eyes, broken skin, or mucous membranes — if accidental contact occurs, rinse thoroughly with water.
• Not intended for use in individuals under 18 years of age.
• Discontinue and consult a physician if chest pain, rapid heartbeat, dizziness, fainting, sudden unexplained weight gain, swelling of hands/feet, or scalp irritation that does not resolve occurs.
• Some topical solutions contain alcohol and are flammable — keep away from open flame or heat sources (e.g. hair dryers) until fully dry.
• See Contraindications and Pregnancy and Lactation for further precautions.

Oral Hairgrow overdose can cause pronounced hypotension, dizziness or fainting, rapid heartbeat, and fluid retention. Accidental ingestion of topical Hairgrow can produce similar systemic effects (marked drop in blood pressure, fluid retention, tachycardia) because the entire topical dose becomes available for absorption if swallowed.

In either case, seek immediate medical attention or contact a poison control center / emergency services right away. Do not attempt home treatment. Take the product packaging with you if going to a hospital or calling for help, so treating clinicians know the exact formulation and strength involved.

Store at room temperature (below 30°C), away from light and moisture. Topical solutions and foams are typically flammable due to their alcohol content — keep away from open flame, cigarettes, and heat sources, and do not use while smoking or near an open flame. Keep the container tightly closed. Keep out of reach of children.

• Renal impairment: Patients with renal disease are more prone to fluid retention and its complications (including pericardial effusion) with oral Hairgrow; lower starting doses and longer intervals between dose increases, along with careful monitoring, are recommended. Some patients may require dialysis to manage fluid overload.
• Hepatic impairment: No specific dose adjustment is well established; use with routine clinical caution as Hairgrow is hepatically metabolized (sulfation).
• Elderly: May be more sensitive to blood-pressure-lowering and fluid-retaining effects of oral Hairgrow; start at the lower end of the dosing range and monitor closely.
• Children: Oral Hairgrow has established pediatric dosing for severe hypertension under specialist supervision (see Dosage). Topical Hairgrow is not recommended for those under 18 years of age, as safety and efficacy have not been established in this group.

Oral: Used long-term as part of ongoing management of resistant hypertension, for as long as clinically indicated; blood pressure control and fluid status should be reassessed regularly by a physician, and the drug should not be stopped abruptly without medical advice.

Topical: A trial of at least 4 months of consistent twice-daily use is usually needed before hair regrowth benefit can be judged; some patients require 6–12 months. Continued use is necessary to sustain any benefit — newly grown hair is typically lost within a few months of discontinuing treatment.

Antihypertensives — peripheral vasodilators (oral); Dermatological agents — topical hair growth stimulants (topical)

Minoxidil is converted to its active form, Minoxidil sulfate, which opens ATP-sensitive potassium (K-ATP) channels in vascular smooth muscle. This hyperpolarizes the cell membrane, closes voltage-gated calcium channels, reduces intracellular calcium, and relaxes arteriolar smooth muscle — producing direct peripheral arteriolar vasodilation and a fall in blood pressure with little effect on veins.

On the scalp, local conversion to Minoxidil sulfate by follicular sulfotransferase is thought to increase blood flow to hair follicles and promote a shift of follicles into, and prolongation of, the anagen (active growth) phase, though the exact mechanism of hair regrowth is not fully established.

C

Oral Hairgrow: Has an established weight-based dosing regimen for severe hypertension in children (see Dosage), used under close specialist supervision given the risks of fluid retention and cardiac effects.

Topical Hairgrow: Safety and efficacy have not been established in individuals under 18 years of age; topical Hairgrow is not recommended for this age group.